Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC Restrictions Under Consideration For House Medicare Rx Bill

Executive Summary

House Ways & Means Committee leadership is considering adding direct-to-consumer advertising restrictions to Medicare prescription drug benefit legislation.
Advertisement

Related Content

Medicare Rx Law Would Fundamentally Change, Not End, Drug Pricing Debate
FDA Readies Report On DTC, Says Physician Survey Supports Current Policy
PDUFA III Funding Level Will Allow Increased Ad Oversight By FDA – HHS
PDUFA III Debate Kicks Off With House Commerce Committee Hearing March 6
House Medicare Rx Bill Could Be Ready For Floor Vote In October
Schering-Plough Claritin DTC Ads Are Target Of Rx Consumer Litigation Group
Medicare Reform Focus Moving To House: Senate Markup Delayed
GPhA Endorses Graham Medicare Rx: Still Needs Finance Cmte. Republican
Thomas/Wyden Medicare Rx Plan Has Royalty On Federally Funded Research
Thomas/Wyden Medicare Rx Plan Has Royalty On Federally Funded Research
Advertisement
UsernamePublicRestriction

Register

PS038289

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel